

+



Inserm

Institut national
de la santé et de la recherche médicale



Institut NeuroMyoGène CNRS UMR 5310 / INSERM U1217

Domaine Scientifique de la Doua - 16 rue Dubois, Bâtiment G. Mendel - 69622 Villeurbanne Cedex
Tel : (33) 0472431325 - Fax : (33) 0472432685 - www.inmg.fr

LES SÉMINAIRES DE L'INMG

*The tumor suppressor LKB1 controls
cell fate through pyruvate-alanine
transamination*

Par

Chantal THIBERT

(Invitée par Julien COURCHET)

**Institute for Advanced Biosciences
Université Grenoble Alpes
Inserm U1209 CNRS UMR5309
France**

Vendredi 1^{er} Décembre 2017
11 heures

**Amphithéâtre
CNRS Rhône Auvergne
2, Av. Albert Einstein
69100 Villeurbanne
Domaine Universitaire de La Doua**

Abstract :

The tumor suppressor *LKB1* (also named *STK11*) codes for a serine/threonine kinase. *LKB1* acts as a key regulator of cell polarity as well as energy metabolism partly through the activation of the AMP-activated protein kinase (AMPK), a sensor that adapts energy supply to the nutrient demands of cells facing situations of metabolic stress.

To determine if *Lkb1* exerts a coordinated regulation of energy metabolism and cell polarity, we deleted the *Lkb1* gene in polarized cells and explored the metabolic consequences. In particular, we generated spatio-temporal ablation of *Lkb1* in a subpopulation of mouse embryonic multipotent neural crest cells (NCC) that originate from the neural tube and give rise to a broad range of derivatives including most of the face, the melanocytes, the peripheral nerves and the enteric nervous system (ENS). Mutant mice exhibited craniofacial malformations, hypopigmentation, intestinal pseudo-obstruction and hindlimb paralysis. Further phenotypic characterization revealed that *LKB1* is required for the differentiation and maintenance of two NCC-derivatives, Schwann cells and the ENS. Using a model of neural crest stem cell line, we demonstrated that *Lkb1* is key for neural crest-derived glial commitment. Mechanistically, *Lkb1* loss led to an increase of alanine and glutamate levels and inhibition of pyruvate-alanine transamination rescued glial differentiation of *Lkb1*-null NCC, in a mTOR dependent manner. Furthermore, AICAR, an analogue of AMP, rescued glial differentiation of *Lkb1*-deficient NCC and corrected the Schwann cells and ENS phenotypes of *Lkb1* mutant mice.

Altogether, these findings highlight the central role of *Lkb1* during neural crest cell lineage and uncovered a link between *Lkb1*-mediated pyruvate-alanine cycling and glial commitment. These results provide also new insights for the understanding of metabolic events that contribute to the formation of *LKB1*-deficient malignancies.